-
1.
公开(公告)号:US20120114667A1
公开(公告)日:2012-05-10
申请号:US13141564
申请日:2009-12-21
申请人: Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人: Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号: A61K39/395 , C07K16/18 , C07H21/04 , C12N15/63 , C12N5/16 , C12P21/06 , A61P35/00 , C07K14/00 , A61K38/00 , A61P29/00 , A61P9/10 , A61P9/00 , A61P5/00 , C12N5/10 , C07K16/00
CPC分类号: C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译: 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地,本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-
公开(公告)号:US20120107324A1
公开(公告)日:2012-05-03
申请号:US13141608
申请日:2009-12-21
申请人: Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
发明人: Catherine Anne Eberlein , Ian Foltz , Jaspal Singh Kang , Jane Kendrew , Avril Alfred , Simon Thomas Barry
IPC分类号: A61K39/395 , C07K14/435 , C07K16/00 , A61P35/00 , C12N15/62 , C12N5/10 , C12P21/08 , C07K5/08 , C07H21/04
CPC分类号: B01F5/0619 , B01F5/0613 , B01F5/0617 , B01F15/00935 , B01F2005/0639
摘要: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
摘要翻译: 本发明涉及针对α5和bgr的靶向结合剂及其用途。 更具体地,本发明涉及针对α5和bgr的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5和bgr1的活性和/或过度产生相关的疾病和作为诊断。
-